Stay updated on Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page.

Latest updates to the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe site footer now identifies the release as v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedA site-wide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence.” The site revision changes from v3.7.1 to v3.7.2; the study record remains unavailable behind a 403 error.SummaryDifference1%

- Check29 days agoChange DetectedThe site revision label in the footer changed from v3.7.0 to v3.7.1; the study page remains unavailable with a 403 Forbidden error.SummaryDifference0.2%

- Check43 days agoChange DetectedThe page now displays a 403 Forbidden error, and core study details such as the title, objectives, eligibility criteria, locations, and contacts have been removed, replaced by the error notice.SummaryDifference20%

- Check50 days agoChange DetectedThe page now displays Revision: v3.7.0, replacing the previous v3.6.6, indicating a platform update that does not change the trial details shown.SummaryDifference0.1%

- Check64 days agoChange DetectedThe revision label on the page was updated from v3.6.5 to v3.6.6, signaling a newer release of the page content.SummaryDifference0.1%

Stay in the know with updates to Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page.